Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into ...
Vor Biopharma is developing novel cell therapies for AML, with trem-cel showing early promise in clinical trials but facing significant funding challenges. Trem-cel aims to enhance relapse-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results